Excellent reply, Surges.If this were a two-bit comapany OBJ were...

Excellent reply, Surges.

If this were a two-bit comapany OBJ were dealing with, I'd say fair enough, and would feel inclined to defer to Martin.

But this is Glaxo, one of the biggest healthcare companies (number 2 globally, I think) doing business. And you have to know that when they do business, they mean business, having worked myself for CSL (who had dealings with Glaxo) during my uni days.

Each and every product gets put under a microscope. What you can't do is put peoples' lives at risk, no matter what the product, and it better do what it says it's gonna do.

Martin, I don't know how long you've been in this thing, but have some patience. At least we don't have to argue or be concerned with a distraction like a Nasdaq Listing.

Let the cards fall as they may, because OBJ would very much have their hands tied on this one.